| 1.82 0 (0%) | 07-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.39 | 1-year : | 2.61 |
| Resists | First : | 2.05 | Second : | 2.24 |
| Pivot price | 1.81  |
|||
| Supports | First : | 1.75 | Second : | 1.45 |
| MAs | MA(5) : | 1.82 |
MA(20) : | 1.82 |
| MA(100) : | 2.37 |
MA(250) : | 9.93 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28.5 |
D(3) : | 27.1 |
| RSI | RSI(14): 43.8 | |||
| 52-week | High : | 63.9 | Low : | 1.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MYMD ] has closed below upper band by 47.3%. Bollinger Bands are 81.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.84 - 1.85 | 1.85 - 1.86 |
| Low: | 1.76 - 1.77 | 1.77 - 1.78 |
| Close: | 1.8 - 1.82 | 1.82 - 1.84 |
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Fri, 26 Jul 2024
MyMD Pharmaceuticals Rebrands as TNF Pharmaceuticals - TipRanks
Mon, 22 Jul 2024
MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. - StockTitan
Tue, 21 May 2024
MyMD Pharmaceuticals Secures Strategic Investments - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 6.6 (%) |
| Shares Short | 264 (K) |
| Shares Short P.Month | 322 (K) |
| EPS | -9.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -50.5 % |
| Return on Equity (ttm) | -101.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.2 |
| PEG Ratio | 0 |
| Price to Book value | 0.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|